Merck Collaborates with ISB to Evaluate the Mechanism of COVID-19 and to Identify Potential Prognostic Biomarkers

 Merck Collaborates with ISB to Evaluate the Mechanism of COVID-19 and to Identify Potential Prognostic Biomarkers

Merck Collaborates with ISB to Evaluate the Mechanism of COVID-19 and to Identify Potential Prognostic Biomarkers

Shots:

  • Merck allied with ISB and a consortium of companies to investigate the molecular mechanisms of SARS-CoV-2 Infection and to identify new targets for potential COVID-19 therapeutics and vaccines
  • The collaboration supports the trial led by ISB and Swedish Medical Center in Seattle. By collecting blood and nasal swabs at different times following a patient’s diagnosis, the researchers plan to accumulate a large data set that incorporates patients’ genomes, proteomes and metabolomes + single-cell analytics of the evolving immune system response and the infection’s effect on different organs
  • Merck will provide research funding and work with ISB researchers to identify targets for drugs, Ab & vaccines and will initially analyze samples from 200 patients with the potential to expand to 300. Additionally, Merck signed an agreement with BARDA to receive funding for supporting the company’s effort

Click here ­to­ read full press release/ article | Ref: Merck | Image: Spagnola and Associates

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post